Liberty Health Sciences (CSE: LHS) (OTC: SCQBD) - Investor Dashboard


➔ Liberty Health Sciences
CSE Ticker: LHS
OTC Ticker: SCQBD
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada/U.S.
Employees: 20
Established: 2017
CEO: George Scorsis

Summary

Fiscal Year-End: June
Auditor: MNP
Licenses: Florida
Licensed Capacity:  Not limited
Number of Patients: <200
Headquarters: Toronto, ON

Financials (Pro Forma as of 3/31/17)

Cash on hand: $11.7mm
Fixed Investment: $0.007mm
Shareholders’ Equity: $70.0mm
Revenues – Last Quarter: $0K
Adj. Gross Margin : N/A
EPS : N/A

Capital Structure (as of 7/25/17)

Last Financing: 54.7mm shares at $0.624
Basic Shares: 284.0mm
Warrants: 3.0mm
Options: 257K
Diluted Shares: 287.3mm

Liberty Health Sciences trades on the Canadian Securities Exchange as “LHS” and is also trading on the OTC as “SCQBD”. The OTC listing will change in roughly 20 trading days from 7/31 to “SCQBF”. Looking for data that isn’t here or have a question? Let us know.


Company Brief

Liberty Health Sciences is one of the first Canadian cannabis companies to focus on cultivation and distribution in the U.S. market. They launched their American expansion in the state of Florida and currently operates and manages one of twelve licenses in that state which has a population of over 20 million people. CEO George Scorsis, a veteran of Red Bull and the former president of Mettrum, a $430mm business prior to its acquisition by Canopy Growth Corp., calls  Liberty the opportunity he has awaited his entire career. Liberty has a strong balance sheet with $10mm in cash and no debt and an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. The company is committed to delivering high-quality, clean and safe pharma-grade cannabis to patients while optimizing returns to shareholders.

CEO George Scorsis


Highlights

  • Operational superiority with support and expertise of its largest investor, Aphria
  • Well-known, highly-regarded management team and Board of Directors
  • Currently one of twelve Florida operators
  • Permitted to open up to 25 dispensaries in Florida

Growth Strategy

  • Entry will be prioritized into states with large populations, multiple approved conditions and no canopy restrictions
  • Acquisition and greenfield (CT, MD, OH, PA are focus areas)
  • Florida production expansion:
    • 2mm gram production capacity by January 2018
    • 25mm gram production capacity by December 2018
  • Florida dispensary additions: Click here to view

Differentiators

  • Aphria support and expertise through Trademark License and Know-How License which encompasses both a proprietary Seed-to-Sale Certified quality assurance process and proprietary automation and processing methods
  • Access to capital
  • Management team and Board of Directors with substantial skin-in-the-game via ownership of shares
  • Committed to delivering high-quality, clean and safe pharmaceutical grade cannabis to American patients

Curated Stories & News


Visit Liberty Health Sciences Inc.,
at www.libertyhealthsciences.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Liberty Health Sciences, Inc. is a client of NCV Media, LLC. Read our full disclaimer.

Latest News
Get The App

Download the free “New Cannabis Ventures” app on the iOS App Store or Google Play and get real-time push notifications straight to your phone on the latest breaking news and exclusives published.


ncv-news-ios-app-store

ncv-news-google-play

NCV Media

Thank you for reading

New Cannabis Ventures

Contributing original content and curating quality news on only the most promising cannabis companies and the most influential investors.

FOLLOW US ON